Alx Oncology Share Price Today
(NASDAQ: ALXO)

Name: Alx Oncology Share Price Today (NASDAQ: ALXO) - Alx Oncology Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Alx Oncology share price is $0.55 & ₹47.01 as on 18 Apr 2025, 2.30 'hrs' IST

$0.55

▲

-0.01

(-1.79%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Alx Oncology share price in Dollar and Rupees. Guide to invest in Alx Oncology stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Alx Oncology, along with analyst recommendations, forecasts, and comprehensive financials.

Alx Oncology share price movements

Today's Low: $0.54
Today's High: $0.57
$0.55
1.38%
Downside
Day's Volatility :5.13%
Upside
3.8%
52 Weeks Low: $0.46
52 Weeks High: $17.83
$0.55
16.36%
Downside
52 Weeks Volatility :97.42%
Upside
96.91%

Alx Oncology (ALXO) Returns

Period	Alx Oncology Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-66.67%	-2.8%	0.0%
6 Months	-63.33%	-11.0%	0.0%
1 Year	-96.47%	-1.9%	0.0%
3 Years	-96.24%	-1.5%	-12.9%

Alx Oncology (ALXO) Key Statistics

in dollars & INR

Previous Close	$0.56
Open	$0.55
Today's High	$0.5717
Today's Low	$0.5424
Market Capitalization	$29.4M
Today's Volume	$337.0K
52 Week High	$17.825
52 Week Low	$0.46
Revenue TTM	$0.0
EBITDA	$-141.6M
Earnings Per Share (EPS)	$-2.58
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-88.91%

How to invest in Alx Oncology Stock (ALXO) from India?

It is very easy for Indian residents to invest directly in Alx Oncology from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Alx Oncology stock in both Indian Rupees (INR) and US Dollars (USD). Search for Alx Oncology or ALXO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Alx Oncology or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Alx Oncology shares which would translate to 1.554 fractional shares of Alx Oncology as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Alx Oncology, in just a few clicks!

Returns in Alx Oncology (ALXO) for Indian investors in Rupees

The Alx Oncology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Alx Oncology investment value today

Current value as on today

₹5,867

Returns

₹94,133

(-94.13%)

Returns from Alx Oncology Stock

₹96,474 (-96.47%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Alx Oncology (ALXO)

-31%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Alx Oncology Stock from India on INDmoney has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Alx Oncology

venBio Partners LLC
18.17%
Redmile Group, LLC
6.91%
TANG CAPITAL MANAGEMENT LLC
6.18%
Morgan Stanley - Brokerage Accounts
4.68%
BlackRock Inc
4.47%
Millennium Management LLC
3.99%

Analyst Recommendation on Alx Oncology

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Alx Oncology(by analysts ranked 0 to 5 stars)

Analyst Forecast on Alx Oncology Stock (ALXO)

What analysts predicted

Upside of 518.18%

Target:

$3.40

Current:

$0.55

Insights on Alx Oncology Stock (Ticker Symbol: ALXO)

Price Movement
In the last 7 days, ALXO stock has moved up by 14.3%
ALXO vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 172.5%
ALXO vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 125.3%

Alx Oncology Technicals Summary

Sell

Neutral

Buy

Alx Oncology is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Alx Oncology (ALXO) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alx Oncology Holdings Inc	-25.18%	-63.33%	-96.47%	-96.24%	-98.17%
Regeneron Pharmaceuticals, Inc.	-17.1%	-41.85%	-37.2%	-21.74%	-0.85%
Beone Medicines Ltd	-13.12%	5.03%	78.34%	40.23%	43.44%
Vertex Pharmaceuticals Incorporated	-4.76%	2.3%	24.05%	71.43%	78.99%
Alnylam Pharmaceuticals, Inc.	-9.09%	-19.67%	62.43%	39.66%	61.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alx Oncology Holdings Inc	NA	NA	NA	-1.14	-0.89	-0.46	NA	2.14
Regeneron Pharmaceuticals, Inc.	14.68	14.68	0.9	41.18	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	17.96	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.81	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alx Oncology Holdings Inc	Buy	$29.4M	-98.17%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$60.5B	-0.85%	14.68	31.07%
Beone Medicines Ltd	NA	$26.9B	43.44%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$125.7B	78.99%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	61.91%	NA	-12.37%

About Alx Oncology

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Organization	Alx Oncology
Employees	80
CEO	Mr. Jason W. Lettmann
Industry	Commercial Services

Management People of Alx Oncology

Name	Title
Mr. Jason W. Lettmann	CEO & Director
Dr. Jaume Pons Ph.D.	Founder, President & Chief Scientific Officer
Mr. Harish Shantharam C.F.A.	Chief Financial Officer
Dr. Michael Chang Ph.D.	Vice President of Operations
Ms. Shelly Pinto CPA	Senior VP of Finance & Chief Accounting Officer and Principal Accounting Officer
Dr. Athanasios Tsiatis M.D.	Senior Vice President of Clinical Development
Dr. Lin Yeong-Liang M.D., M.S.	Senior Vice President of Drug Safety & Pharmacovigilance
Ms. Lisa Sauer	Senior Vice President of Regulatory Affairs & Quality Assurance
Ms. Sue Naim	Senior Vice President of Clinical Operations
Dr. Allison Dillon Ph.D.	Chief Business Officer

Important FAQs about investing in ALXO Stock from India :

What is Alx Oncology share price today?

Alx Oncology share price today stands at $0.55, Open: $0.55 ; Previous Close: $0.56 ; High: $0.57 ; Low: $0.54 ; 52 Week High: $17.83 ; 52 Week Low: $0.46.

The stock opens at $0.55, after a previous close of $0.56. The stock reached a daily high of $0.57 and a low of $0.54, with a 52-week high of $17.83 and a 52-week low of $0.46.

Can Indians buy Alx Oncology shares?

Yes, Indians can invest in the Alx Oncology (ALXO) from India.

With INDmoney, you can buy Alx Oncology at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Alx Oncology at zero transaction cost.

How can I buy Alx Oncology shares from India?

It is very easy to buy Alx Oncology from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Alx Oncology (ALXO) be purchased?

Yes, you can buy fractional shares of Alx Oncology with INDmoney app.

What are the documents required to start investing in Alx Oncology stocks?

To start investing in Alx Oncology, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.